What is Neurocrine Biosciences's net change in cash?

Neurocrine Biosciences (NBIX) reported net change in cash of -$446.5M in Q1 2026.

How has Neurocrine Biosciences's net change in cash changed year-over-year?

Neurocrine Biosciences's net change in cash decreased by 1047.8% year-over-year, from -$38.9M to -$446.5M.

What does net change in cash mean?

Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Neurocrine Biosciences NBIX Net Change in Cash

Net Change in Cash at other companies

Bristol-Myers SquibbBMY

-$861M-150%

Acadia PharmaceuticalsACAD

$104.52M+203%

Crinetics PharmaceuticalsCRNX

$12.81M+108%

Solid Biosciences Inc.SLDB

$236.56M+81.4%

MapLight Therapeutics, Inc. MPLT

$8.98M-24.6%

BridgeBio PharmaBBIO

$309.88M+321%

Other financials

Income statement

See full

Revenue$814.5M+42.2%

Gross profit$800.7M+42.1%

Operating income$193.4M+719%

Net income$197.9M+2,405%

EPS (diluted)$1.91+2,287%

Balance sheet

See full

Cash & equivalents$274.5M+35.8%

Total debt$463.5M-6.0%

Total equity$3.4B+34.4%

Total assets$4.9B+33.0%

Cash flow

See full

Operating cash flow$145.8M+125%

CapEx$9.1M-15.0%

Free cash flow$136.7M+153%

Valuation

See full

Market cap$18.18B+34.3%

Enterprise value$18.37B+33.6%

P/E27.2×-11.7×

P/S5.9×+0.5×

Profitability

See full

Gross margin98.2%-0.3pp

Operating margin25.4%+4.9pp

Net margin21.6%+8.9pp

FCF margin26.8%+6.4pp

Returns & leverage

See full

Return on equity22.5%+10.1pp

Debt / equity0.1×-0.1×

Current ratio2.9×-0.2×

Where this comes from

Reported directly by Neurocrine Biosciences in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neurocrine Biosciences's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Neurocrine Biosciences's net change in cash?: Neurocrine Biosciences (NBIX) reported net change in cash of -$446.5M in Q1 2026.
How has Neurocrine Biosciences's net change in cash changed year-over-year?: Neurocrine Biosciences's net change in cash decreased by 1047.8% year-over-year, from -$38.9M to -$446.5M.
What does net change in cash mean?: Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.